135 related articles for article (PubMed ID: 2337121)
1. Protamine antibody production in diabetic subjects treated with NPH insulin.
Ellerhorst JA; Comstock JP; Nell LJ
Am J Med Sci; 1990 May; 299(5):298-301. PubMed ID: 2337121
[TBL] [Abstract][Full Text] [Related]
2. Immunologic analysis of anaphylaxis to protamine component in neutral protamine Hagedorn human insulin.
Dykewicz MS; Kim HW; Orfan N; Yoo TJ; Lieberman P
J Allergy Clin Immunol; 1994 Jan; 93(1 Pt 1):117-25. PubMed ID: 8308177
[TBL] [Abstract][Full Text] [Related]
3. Circulating IgG antibody to protamine in patients treated with protamine-insulins.
Kurtz AB; Gray RS; Markanday S; Nabarro JD
Diabetologia; 1983 Oct; 25(4):322-4. PubMed ID: 6196244
[TBL] [Abstract][Full Text] [Related]
4. Platelet activation in the presence of neutral protamine Hagedorn insulin: a new feature of antibodies against protamine/heparin complexes.
Zöllner H; Jouni R; Panzer S; Khadour A; Janzen L; Wesche J; Ten Berg M; Schellong S; Heinken A; Greinacher A; Bakchoul T
J Thromb Haemost; 2017 Jan; 15(1):176-184. PubMed ID: 27759896
[TBL] [Abstract][Full Text] [Related]
5. Frequency and specificity of protamine antibodies in diabetic and control subjects.
Nell LJ; Thomas JW
Diabetes; 1988 Feb; 37(2):172-6. PubMed ID: 3292313
[TBL] [Abstract][Full Text] [Related]
6. Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization.
Stewart WJ; McSweeney SM; Kellett MA; Faxon DP; Ryan TJ
Circulation; 1984 Nov; 70(5):788-92. PubMed ID: 6488493
[TBL] [Abstract][Full Text] [Related]
7. Protamine allergy reactions during cardiac catheterization and cardiac surgery: risk in patients taking protamine-insulin preparations.
Vincent GM; Janowski M; Menlove R
Cathet Cardiovasc Diagn; 1991 Jul; 23(3):164-8. PubMed ID: 1831070
[TBL] [Abstract][Full Text] [Related]
8. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
[TBL] [Abstract][Full Text] [Related]
9. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
10. Anaphylaxis to subcutaneous neutral protamine Hagedorn insulin with simultaneous sensitization to protamine and insulin.
Blanco C; Castillo R; Quiralte J; Delgado J; García I; de Pablos P; Carrillo T
Allergy; 1996 Jun; 51(6):421-4. PubMed ID: 8837667
[TBL] [Abstract][Full Text] [Related]
11. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.
Rosenstock J; Fonseca V; McGill JB; Riddle M; Hallé JP; Hramiak I; Johnston P; Davis M
Diabetologia; 2009 Sep; 52(9):1778-88. PubMed ID: 19526210
[TBL] [Abstract][Full Text] [Related]
12. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.
Imbergamo MP; Amato MC; Sciortino G; Gambina M; Accidenti M; Criscimanna A; Giordano C; Galluzzo A
Clin Ther; 2008 Aug; 30(8):1476-84. PubMed ID: 18803989
[TBL] [Abstract][Full Text] [Related]
13. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
[TBL] [Abstract][Full Text] [Related]
14. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
Owens DR; Traylor L; Mullins P; Landgraf W
Diabetes Res Clin Pract; 2017 Feb; 124():57-65. PubMed ID: 28092788
[TBL] [Abstract][Full Text] [Related]
15. Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis.
Lee P; Chang A; Blaum C; Vlajnic A; Gao L; Halter J
J Am Geriatr Soc; 2012 Jan; 60(1):51-9. PubMed ID: 22239291
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients.
Dhital SM; Shenker Y; Meredith M; Davis DB
Endocr Pract; 2012; 18(5):712-9. PubMed ID: 22784834
[TBL] [Abstract][Full Text] [Related]
17. Bovine and human NPH insulins as T cell immunogens.
Gregory R; Tattersall RB
Diabetes Res Clin Pract; 1993 May; 20(2):139-46. PubMed ID: 8375267
[TBL] [Abstract][Full Text] [Related]
18. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
19. Intermediate-acting insulin preparations: NPH and lente.
Deckert T
Diabetes Care; 1980; 3(5):623-6. PubMed ID: 7192205
[TBL] [Abstract][Full Text] [Related]
20. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study.
Sreenan S; Virkamäki A; Zhang K; Hansen JB;
Int J Clin Pract; 2008 Dec; 62(12):1971-80. PubMed ID: 19166444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
